Non-contrast spectral CT for differentiating hepatic hemangioma from hepatocellular carcinoma in chronic liver disease
Frontiers in Oncology · 18.11.2026 · 16
DOI: 10.3389/fonc.2026.1967307 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 18.11.2026. Verfasst von Qinghong Yan und 6 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To evaluate quantitative non-contrast dual-layer detector spectral CT (DLCT) for differentiating hepatic hemangioma (HH) from hepatocellular carcinoma (HCC) in chronic liver disease (CLD).
Methods
This retrospective study included 90 patients with CLD and 92 focal liver lesions (35 HHs, 57 HCCs) who underwent non-contrast and multiphase contrast-enhanced DLCT between September 2023 and April 2026. Diagnoses were established by pathology or typical CT/MRI findings with clinical follow-up. Clinical variables and DLCT parameters, including virtual monoenergetic CT attenuation, spectral attenuation curve slopes, effective atomic number (Zeff), and electron density (ED), were assessed. Clinical, DLCT, and combined logistic regression models were evaluated using repeated nested cross-validation.
Results
Compared with HHs, HCCs were associated with older age, more frequent cirrhosis and alpha-fetoprotein positivity, larger maximum lesion diameter, and more frequent abnormal albumin and total bilirubin levels (all p < 0.05). HU40, λHU40–100, and Zeff were higher in HCCs, whereas HU100, HU140, and ED were lower (all p < 0.05). Alpha-fetoprotein, maximum lesion diameter, Zeff, and ED were independent predictors. In outer cross-validation, the combined model showed the highest performance (AUC, 0.814; 95% CI, 0.806–0.823), with sensitivity, specificity, and accuracy of 0.723, 0.761, and 0.738. It outperformed the clinical and DLCT models (both p < 0.001) and improved reclassification over both.
Conclusion
Non-contrast DLCT parameters, particularly Zeff and ED, help differentiate HH from HCC in CLD. Their combination with clinical variables improved discrimination and risk reclassification.
Zitieren
APA
Yan, Q., Jing, Y., Liu, Y., Liu, Y., Xu, X., Hao, M., & Ren, T. (2026). Non-contrast spectral CT for differentiating hepatic hemangioma from hepatocellular carcinoma in chronic liver disease. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1967307
Vancouver
Yan Q, Jing Y, Liu Y, Liu Y, Xu X, Hao M, et al. Non-contrast spectral CT for differentiating hepatic hemangioma from hepatocellular carcinoma in chronic liver disease. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1967307
BibTeX
@article{Yan2026,
author = {Yan, Qinghong and Jing, Yunhang and Liu, Yangsen and Liu, Yihan and Xu, Xingyue and Hao, Mengyuan and Ren, Tao},
title = {Non-contrast spectral CT for differentiating hepatic hemangioma from hepatocellular carcinoma in chronic liver disease},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1967307}
}
EUVIMED